Shareholder Action

     RALEIGH, N.C. – A shareholder class action claims Cempra Inc. and its executives failed to disclose that an antibiotic it developed to treat bacterial pneumonia and urethritis poses significant health risks to some individuals. The class claims when this information became public, the value of their shares dropped from $18.65 to $7.30 in a single day.